Background Pancreatic ductal adenocarcinoma (PDAC) is notoriously resistant to treatment
including checkpoint-blockade immunotherapy. We hypothesized that a bimodal treatment …

Cancer immunotherapies are more effective in tumors with robust T cell infiltrates, but
mechanisms to convert T cell-devoid tumors with active immunosuppression to those …

Pancreatic ductal adenocarcinoma (PDA) is a highly aggressive and lethal cancer which is
poorly responsive to standard therapies. Although the PDA tumor microenvironment is …

Objectives With the poorest 5‐year survival of all cancers, improving treatment for pancreatic
cancer is one of the biggest challenges in cancer research. We sought to explore the …

Pancreatic ductal adenocarcinoma (PDAC) is resistant to the PD-1/PD-L1 blockade therapy.
Previously, the combination of PD-1 blockade and vaccine therapy was shown to have a …

Myeloid cells facilitate T cell immune evasion in cancer yet are pliable and have antitumor
potential. Here, by cotargeting myeloid activation molecules, we leveraged the myeloid …

Despite the availability of recently developed chemotherapy regimens, survival times for
pancreatic cancer patients remain poor. These patients also respond poorly to immune …

Previous fundamental or clinical trials of dendritic cell (DC) vaccine against pancreatic
ductal adeno carcinoma (PDAC) revealed the burgeoning neoadjuvant immunotherapy …

Disabling the function of immune checkpoint molecules can unlock T-cell immunity against
cancer, yet despite remarkable clinical success with monoclonal antibodies (mAb) that block …

Cancer immunotherapies are increasingly effective in the clinic, especially immune
checkpoint blockade delivered to patients who have T cell–infiltrated tumors. Agonistic …